Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 20;10(1):e17436.
doi: 10.2196/17436.

Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study

Judith White  1 , Laura Knight  1 , Lyndon da Cruz  2 , Paulo E Stanga  3   4 , Hannah Patrick  5 , Helen Powell  5 , Lee Berry  5 , Kathleen Withers  1 , Grace Carolan-Rees  1 , Timothy L Jackson  6
Affiliations

Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study

Judith White et al. JMIR Res Protoc. .

Abstract

Background: Retinitis pigmentosa is an incurable, degenerative retinal condition causing progressive sight loss, significantly affecting patients' quality of life. The Argus II Retinal Prosthesis is a surgically implanted medical device that delivers electrical stimulation to the retina. It is intended to produce a form of artificial vision for blind people with severe-to-profound retinitis pigmentosa by stimulating the remaining viable retinal cells to induce visual perception. This study has been initiated by National Health Service England's Commissioning through Evaluation program and funded through the National Institute of Health Research of the United Kingdom.

Objective: The aim of this study was to assess the effect of the Argus II device on patient's daily activities and quality of life.

Methods: This protocol is a prospective, single-arm, open-label, mixed methods study on 10 consecutive participants receiving the Argus II device. The patient representatives played an integral role in the design of this study. Eligibility criteria include ultra-low vision in both eyes as a result of end-stage retinitis pigmentosa and a willingness and capacity to complete the postimplantation rehabilitation program. Participants will be interviewed by independent researchers at baseline and 12 months later by using a semistructured, in-depth approach, alongside validated questionnaires (Impact of Vision Impairment-Very Low Vision, 5-level EuroQoL-5 dimensions scale, EuroQoL-visual analog scale, and Hospital Anxiety and Depression Scale) and a bespoke device-related questionnaire, which includes questions about users' experiences with the procedure, the device, and rehabilitation. The effect of the device on patients' functional vision and activities of daily living will be assessed by vision rehabilitation specialists using a set of tests measured on an ordinal scale (eg, ability to locate objects and avoid obstacles). Clinical outcomes include full-field stimulus light threshold, square localization, direction of motion, grating visual acuity, Landolt-C, procedural success, and adverse events. Qualitative and quantitative outcomes will be linked in a single database to enable individual participant measures to be considered in toto, comparing baseline to the final review.

Results: This study was approved by the local ethics committee on April 24, 2019 (London-Camberwell St. Giles Research Ethics Committee, reference 19/LO/0429). It has also been approved by the Health Research Authority and Health and Care Research Wales. At the time of protocol writing, Argus II was available for use in the United Kingdom; however, the manufacturer recently withdrew the Argus II device from sale in the United Kingdom. Therefore, the study is not going ahead at this time.

Conclusions: The mixed methods approach provides a rich and in-depth assessment of the effect of the device on participants' quality of life. Despite the work not going ahead, the publication of this publicly funded protocol is important for researchers planning similar work.

International registered report identifier (irrid): PRR1-10.2196/17436.

Keywords: artificial vision; functional vision; low vision; patient-reported outcomes; qualitative methods; quality of life; ultra-low vision; visual function; visual function questionnaire.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: LdC and PES were investigators and surgeons in the Argus II feasibility study (NCT00407602). PES has undertaken consultancy for Second Sight. The remaining authors (JW, LK, LdC, H Patrick, H Powell, LB, KW, GCR, and TLJ) report no financial or nonfinancial interest related to this project.

Figures

Figure 1
Figure 1
Argus II retinal prosthesis components.
See this image and copyright information in PMC

References

    1. Retinitis pigmentosa: What is retinitis pigmentosa? Fight for Sight. 2019. [2021-01-04]. https://www.fightforsight.org.uk/about-the-eye/a-z-eye-conditions/retini...
    1. Ledford H. FDA advisers back gene therapy for rare form of blindness. Nature. 2017 Oct 12;550(7676):314. doi: 10.1038/nature.2017.22819. - DOI - PubMed
    1. Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, de Juan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley A, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT. Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol. 2016 May 06;16:52. doi: 10.1186/s12886-016-0225-1. https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-016-0225-1 - DOI - DOI - PMC - PubMed
    1. Insertion of an epiretinal prosthesis for retinitis pigmentosa: Interventional procedures guidance [IPG519] National Institute for Health and Care Excellence. 2015. Jun 25, [2021-01-04]. https://www.nice.org.uk/Guidance/IPG519.
    1. da Cruz L, Dorn JD, Humayun MS, Dagnelie G, Handa J, Barale P, Sahel J, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch D, Spencer R, Cideciyan AV, de Juan E, Duncan JL, Eliott D, Fawzi A, Olmos de Koo LC, Ho AC, Brown G, Haller J, Regillo C, Del Priore LV, Arditi A, Greenberg RJ, Argus II Study Group Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial. Ophthalmology. 2016 Oct;123(10):2248–54. doi: 10.1016/j.ophtha.2016.06.049. https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(16)30579-6 - DOI - PMC - PubMed

LinkOut - more resources